102 related articles for article (PubMed ID: 26639308)
1. Structure-Activity Relationships of JMV4463, a Vectorized Cathepsin D Inhibitor with Antiproliferative Properties: The Unique Role of the AMPA-Based Vector.
Vezenkov LL; Sanchez CA; Bellet V; Martin V; Maynadier M; Bettache N; Lisowski V; Martinez J; Garcia M; Amblard M; Hernandez JF
ChemMedChem; 2016 Feb; 11(3):302-8. PubMed ID: 26639308
[TBL] [Abstract][Full Text] [Related]
2. Dipeptide mimic oligomer transporter mediates intracellular delivery of Cathepsin D inhibitors: a potential target for cancer therapy.
Maynadier M; Vezenkov LL; Amblard M; Martin V; Gandreuil C; Vaillant O; Gary-Bobo M; Basile I; Hernandez JF; Garcia M; Martinez J
J Control Release; 2013 Oct; 171(2):251-7. PubMed ID: 23899821
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cathepsin D by substrate analogues containing statine and by analogues of pepstatin.
Agarwal NS; Rich DH
J Med Chem; 1986 Dec; 29(12):2519-24. PubMed ID: 3783611
[TBL] [Abstract][Full Text] [Related]
4. Replacement of isobutyl by trifluoromethyl in pepstatin A selectively affects inhibition of aspartic proteinases.
Binkert C; Frigerio M; Jones A; Meyer S; Pesenti C; Prade L; Viani F; Zanda M
Chembiochem; 2006 Jan; 7(1):181-6. PubMed ID: 16307463
[TBL] [Abstract][Full Text] [Related]
5. Hybrid 2D/3D-quantitative structure-activity relationship and modeling studies perspectives of pepstatin A analogs as cathepsin D inhibitors.
Arodola OA; Soliman ME
Future Med Chem; 2018 Jan; 10(1):5-26. PubMed ID: 29235371
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cathepsin D by tripeptides containing statine analogs.
Bessodes M; Antonakis K; Herscovici J; Garcia M; Rochefort H; Capony F; Lelièvre Y; Scherman D
Biochem Pharmacol; 1999 Jul; 58(2):329-33. PubMed ID: 10423175
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of aspartic proteases by pepstatin and 3-methylstatine derivatives of pepstatin. Evidence for collected-substrate enzyme inhibition.
Rich DH; Bernatowicz MS; Agarwal NS; Kawai M; Salituro FG; Schmidt PG
Biochemistry; 1985 Jun; 24(13):3165-73. PubMed ID: 3927973
[TBL] [Abstract][Full Text] [Related]
8. Biological activity of aspartic proteinase inhibitors related to pepstatin.
Gunn JM; Owens RA; Liu WS; Glover GI
Acta Biol Med Ger; 1981; 40(10-11):1547-53. PubMed ID: 6805191
[TBL] [Abstract][Full Text] [Related]
9. Structure-based subsite specificity mapping of human cathepsin D using statine-based inhibitors.
Majer P; Collins JR; Gulnik SV; Erickson JW
Protein Sci; 1997 Jul; 6(7):1458-66. PubMed ID: 9232647
[TBL] [Abstract][Full Text] [Related]
10. Lower homologues of ahpatinin, aspartic protease inhibitors, from a marine Streptomyces sp.
Sun Y; Takada K; Nogi Y; Okada S; Matsunaga S
J Nat Prod; 2014 Jul; 77(7):1749-52. PubMed ID: 24960234
[TBL] [Abstract][Full Text] [Related]
11. Probing the cathepsin D using a BODIPY FL-pepstatin A: applications in fluorescence polarization and microscopy.
Chen CS; Chen WN; Zhou M; Arttamangkul S; Haugland RP
J Biochem Biophys Methods; 2000 Mar; 42(3):137-51. PubMed ID: 10737220
[TBL] [Abstract][Full Text] [Related]
12. Pepstatin inhibition mechanism.
Marciniszyn J; Hartsuck JA; Tang J
Adv Exp Med Biol; 1977; 95():199-210. PubMed ID: 339690
[TBL] [Abstract][Full Text] [Related]
13. A novel cell penetrating aspartic protease inhibitor blocks processing and presentation of tetanus toxoid more efficiently than pepstatin A.
Zaidi N; Burster T; Sommandas V; Herrmann T; Boehm BO; Driessen C; Voelter W; Kalbacher H
Biochem Biophys Res Commun; 2007 Dec; 364(2):243-9. PubMed ID: 17937927
[TBL] [Abstract][Full Text] [Related]
14. Prolongation of serum half-life of interleukin 2 and augmentation of lymphokine-activated killer cell activity by pepstatin in mice.
Ohnishi H; Lin KM; Chu TM
Cancer Res; 1990 Feb; 50(4):1107-12. PubMed ID: 2297759
[TBL] [Abstract][Full Text] [Related]
15. Cathepsin D inhibitors as potential therapeutics for breast cancer treatment: Molecular docking and bioevaluation against triple-negative and triple-positive breast cancers.
Anantaraju HS; Battu MB; Viswanadha S; Sriram D; Yogeeswari P
Mol Divers; 2016 May; 20(2):521-35. PubMed ID: 26563150
[TBL] [Abstract][Full Text] [Related]
16. No role for pepstatin-A-sensitive acidic proteinases in reovirus infections of L or MDCK cells.
Kothandaraman S; Hebert MC; Raines RT; Nibert ML
Virology; 1998 Nov; 251(2):264-72. PubMed ID: 9837790
[TBL] [Abstract][Full Text] [Related]
17. Cathepsin D--a main proteolytic enzyme of the bovine vitreous.
Galewska Z; Bańkowski E
Rocz Akad Med Bialymst; 1994; 39():38-43. PubMed ID: 7497083
[TBL] [Abstract][Full Text] [Related]
18. HSP70 inhibition by 2-phenylethynesulfonamide induces lysosomal cathepsin D release and immunogenic cell death in primary effusion lymphoma.
Granato M; Lacconi V; Peddis M; Lotti LV; Di Renzo L; Gonnella R; Santarelli R; Trivedi P; Frati L; D'Orazi G; Faggioni A; Cirone M
Cell Death Dis; 2013 Jul; 4(7):e730. PubMed ID: 23868063
[TBL] [Abstract][Full Text] [Related]
19. Structure-based optimization of non-peptidic Cathepsin D inhibitors.
Grädler U; Czodrowski P; Tsaklakidis C; Klein M; Werkmann D; Lindemann S; Maskos K; Leuthner B
Bioorg Med Chem Lett; 2014 Sep; 24(17):4141-50. PubMed ID: 25086681
[TBL] [Abstract][Full Text] [Related]
20. Effects of E-64 (cysteine-proteinase inhibitor) and pepstatin (aspartyl-proteinase inhibitor) on metastasis formation in mice with mammary and ovarian tumors.
Leto G; Pizzolanti G; Tumminello FM; Gebbia N
In Vivo; 1994; 8(2):231-6. PubMed ID: 7919127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
